Rapamycin-Eluting Vertebral Stents In The Real-World Treatment of Symptomatic Intracranial Atherosclerotic Stenosis

• Age ≥18 and ≤80 years;
• Symptomatic intracranial atherosclerotic stenosis patients with ineffective medical treatment;
• Digital subtraction angiography (DSA) shows target lesion stenosis ≥70%;
• Suitable for implantation of rapamycin-targeted drug-eluting stents;
• The patient and/or their authorized representative can understand the study purpose, agree to participate, and sign the informed consent form.

Exclusion Criteria:

• Modified Rankin Scale (mRS) score ≥3;
• Ischemic stroke within the past 2 weeks;
• Presence of more than 2 intracranial atherosclerotic stenosis lesions requiring interventional treatment;
• Severe contraindications to heparin, aspirin, ticagrelor, clopidogrel, or other antiplatelet drugs, and inability to tolerate anticoagulant/antiplatelet therapy;
• Severe dysfunction of major organs (e.g., severe hepatic insufficiency, renal insufficiency, heart failure);
• Severe allergies to contrast agents, rapamycin and its derivatives, cobalt-based alloys, or polylactic acid;
• Pregnant or lactating women;
• Participation in other drug or device studies without reaching the endpoint;
• Life expectancy less than 12 months;
• Lesions or vascular access deemed unsuitable for rapamycin drug-eluting stent implantation by the operator.